Dr Reddys Laboratories clarifies on news item

28 Sep 2015 Evaluate

With reference to the news reported in (MINT 26/09/2015) - ‘Dr. Reddys to buy IP rights of Alchemias fondaparinux drug for Rs 116 cr’, Dr Reddys Laboratories has clarified to observation on today’s movement of their share price, in their opinion, is due to the approval by the US FDA and subsequent launch of our high value generic Esomeprazole product in the US market. They would also like to clarify that the aforementioned news article regarding purchase of IP rights for Alchemia drug at Rs 116 cr is a transaction in the regular course of the business. They already have an existing technology licensing agreement with Alchemia. Proposed transaction just represents a conversion of the said licensing agreement into a proposed IP ownership structure. At this stage they have only signed a binding term sheet with the party and a definitive agreement has not yet been reached. Further, they believe that the impact of this transaction is not material to its operations, warranting stock exchange intimation under clause 36 of the Listing Agreement.

The above information is a part of company’s filings submitted to BSE.

Dr. Reddys Lab Share Price

1208.45 -15.85 (-1.29%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×